I agree that this site is using cookies. You can find further informations here.
X
Indrová, M.
~ 0  results:
Search for persons X
?
1

297 Therapy of murine HPV 16-associated TC-1 tumours: suppr..:

Indrova, M. ; Bieblova, J. ; Simova, J....
European Journal of Cancer Supplements.  8 (2010)  5 - p. 77 , 2010
Link: https://doi.org/10.1016/..
 
?
2

960 Therapy of MHC class I+ and class I- HPV16-associated t..:

Bubenik, J. ; Mikyskova, R. ; Indrova, M.
European Journal of Cancer Supplements.  1 (2003)  5 - p. S288-S289 , 2003
Link: https://doi.org/10.1016/..
 
?
3

Therapy of HPV16-induced carcinomas with IL-2 gene modified..:

Bubenik, J. ; Vonka, V. ; Šímová, J....
European Journal of Cancer.  37 (2001)  - p. S161 , 2001
Link: https://doi.org/10.1016/..
 
?
4

Interleukin-2 gene therapy of surgical minimal residual tum..:

Vlk, V. ; Rössner, P. ; Indrová, M...
International Journal of Cancer.  76 (1998)  1 - p. 115-119 , 1998
Link: https://doi.org/10.1002/..
 
?
5

Cross-reactivity of murine and hamster IL-2 mitogenic signa:

Sobotková, E. ; Indrová, M. ; Šímová, J...
Immunology Letters.  50 (1996)  1-2 - p. 115-117 , 1996
Link: https://doi.org/10.1016/..
 
?
6

Interleukin-2 gene therapy of residual EL-4 leukaemia poten..:

Bubeník, J. ; Šímová, J. ; Bubeníková, D...
Journal of Cancer Research and Clinical Oncology.  121 (1995)  1 - p. 39-43 , 1995
Link: https://doi.org/10.1007/..
 
?
7

The influence of tumor immunity suppressors on the effector..:

Abronina, I.F. ; Indrova, M. ; Bubenic, J....
Biomedicine & Pharmacotherapy.  47 (1993)  9 - p. 371-377 , 1993
Link: https://doi.org/10.1016/..
 
?
8

Utilization of lymphoid cells with inserted IL-2 gene for i..:

Bubenik, J. ; Simová, J. ; Indrová, M..
European Journal of Cancer and Clinical Oncology.  27 (1991)  - p. S72 , 1991
Link: https://doi.org/10.1016/..
 
?
9

Lymphokine-activated killer (LAK) cells: I. Age-dependent d..:

Bubeník, J. ; Cinader, B. ; Indrová, M...
Immunology Letters.  16 (1987)  2 - p. 113-119 , 1987
Link: https://doi.org/10.1016/..
 
?
10

Cancer immunotherapy using local interleukin 2 administrati..:

Bubeník, J. ; Indrová, M.
Immunology Letters.  16 (1987)  3-4 - p. 305-309 , 1987
Link: https://doi.org/10.1016/..
 
?
11

Recombinant interleukin-2 inhibits growth of human tumor xe..:

BUBENIK, J ; KIELER, J ; TROMHOLT, V..
Immunology Letters.  14 (1987)  4 - p. 325-330 , 1987
Link: https://doi.org/10.1016/..
 
?
12

Antitumour efficacy of human recombinant interleukin 2:

Bubeník, J. ; Kieler, J. ; Indrová, M.
European Journal of Cancer and Clinical Oncology.  23 (1987)  11 - p. 1738 , 1987
Link: https://doi.org/10.1016/..
 
?
13

Thein vitro cytotoxic effect of Bilirubin on human lymphocy..:

Miler, I. ; Indrová, M. ; Bubeník, J..
Folia Microbiologica.  30 (1985)  3 - p. 272-276 , 1985
Link: https://doi.org/10.1007/..
 
?
14

Growth inhibition of a MC-induced mouse sarcoma by TCGF (IL..:

Bubeník, J. ; Perlmann, P. ; Indrová, M....
Cancer Immunology Immunotherapy.  14 (1983)  3 - p. 205-206 , 1983
Link: https://doi.org/10.1007/..
 
?
15

Solubilized tumour‐associated antigens of methyl‐cholanthre..:

Bubeník, J. ; Indrová, M. ; Nemečková, Š....
International Journal of Cancer.  21 (1978)  3 - p. 348-355 , 1978
Link: https://doi.org/10.1002/..
 
1-15